Beyond Motor Neurons in Spinal Muscular Atrophy: A Focus on Neuromuscular Junction
Spinal muscular atrophy (SMA) is a prevalent neuromuscular disease caused by mutations in the SMN1 gene, leading to motor neuron degeneration. Recent research highlights the involvement of the neuromuscular junction (NMJ) in SMA, offering potential therapeutic targets. Disease-modifying treatments like Nusinersen, Risdiplam, and Onasemnogene Abeparvovec have shown efficacy, particularly when initiated early. The article reviews the pathogenesis of NMJ dysfunction in SMA, discusses circulating biomarkers, and explores therapeutic approaches targeting NMJ. It emphasizes the need for further research to assess NMJ involvement and optimize treatment strategies.

Style rédactionnelInformatif
The article is a narrative review with a focus on scientific findings and therapeutic approaches.


